Ideal Start Market Access for Pharmaceutical Sector Should be 18 months Ahead of Launch, Survey Says

Cutting Edge Information reported that a new pharmaceutical industry study found that among surveyed companies, market access teams would prefer to start working on products an average of 4.6 months before they currently start supporting new products. In terms of launch sequencing and health economics research, market access teams would like at least a year and a half before product launches.
According to the press release:

The report, Managing Market Access Launch Activities: Benchmarking Product Commercialization and Cross-Functional Coordination, examines how companies are managing products in the launch window and the pre-launch preparations necessary for a successful product launch. On average, market access teams would ideally prefer to start conducting products support activities 18.7 months before launch, compared with 14.1 months currently.

Jacob Presson, senior analyst at Cutting Edge Information commented: ]

Getting market access teams involved earlier allows them to begin laying the groundwork for a successful launch. Our research has found that allowing more pre-launch time for market access teams to build effective value cases can make the difference in today’s price-sensitive pharmaceutical market.
For health economics in particular, a longer lead-in period allows a greater flexibility that adding money in the form of higher budgets simply cannot buy. Clinical studies cannot be rushed and so more time before launch allows teams to collect more robust data to support a new product.

Click here to view the full press release.